FFPE Tissue Samples for Genomics Study and Analysis Market Size to Hit USD 1,548.29 Bn by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Ventricular Tachycardia Market

5.1. COVID-19 Landscape: Ventricular Tachycardia Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Ventricular Tachycardia Market, By Sample Type

8.1. Ventricular Tachycardia Market Revenue and Volume, by Sample Type

8.1.1. Blocks

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Slides

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Scrolls

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Curls

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Sections

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Others (Cores, Punches)

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Ventricular Tachycardia Market, By Nucleic Acid Type (Downstream Application)

9.1. Ventricular Tachycardia Market Revenue and Volume, by Nucleic Acid Type (Downstream Application)

9.1.1. DNA-based Genomic Analysis

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. RNA-based Genomic Analysis

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Ventricular Tachycardia Market, By Technology

10.1. Ventricular Tachycardia Market Revenue and Volume, by Technology

10.1.1. Next-Generation Sequencing (NGS)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Microarrays

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. PCR/qPCR

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Digital PCR (dPCR)

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Sanger Sequencing

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Nanostring and Other Platforms

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Ventricular Tachycardia Market, By Application

11.1. Ventricular Tachycardia Market Revenue and Volume, by Application

11.1.1. Cancer Genomics

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Infectious Diseases Genomics

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Neurological Disease Genomics

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Rare Disease Research

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Pharmacogenomics

11.1.5.1. Market Revenue and Volume Forecast

11.1.6. Biomarker Discovery and Validation

11.1.6.1. Market Revenue and Volume Forecast

11.1.7. Population Health Studies

11.1.7.1. Market Revenue and Volume Forecast

Chapter 12. Global Ventricular Tachycardia Market, By End User

12.1. Ventricular Tachycardia Market Revenue and Volume, by End User

12.1.1. Academic & Research Institutes

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Contract Research Organizations (CROs)

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Biopharmaceutical & Biotechnology Companies

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Hospitals & Diagnostic Laboratories

12.1.4.1. Market Revenue and Volume Forecast

12.1.5. Biobanks & Tissue Repositories

12.1.5.1. Market Revenue and Volume Forecast

Chapter 13. Global Ventricular Tachycardia Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Sample Type

13.1.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.1.3. Market Revenue and Volume Forecast, by Technology

13.1.4. Market Revenue and Volume Forecast, by Application

13.1.5. Market Revenue and Volume Forecast, by End User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Sample Type

13.1.6.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.1.6.3. Market Revenue and Volume Forecast, by Technology

13.1.6.4. Market Revenue and Volume Forecast, by Application

13.1.6.5. Market Revenue and Volume Forecast, by End User

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Sample Type

13.1.7.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.1.7.3. Market Revenue and Volume Forecast, by Technology

13.1.7.4. Market Revenue and Volume Forecast, by Application

13.1.7.5. Market Revenue and Volume Forecast, by End User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Sample Type

13.2.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.2.3. Market Revenue and Volume Forecast, by Technology

13.2.4. Market Revenue and Volume Forecast, by Application

13.2.5. Market Revenue and Volume Forecast, by End User

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Sample Type

13.2.6.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.2.6.3. Market Revenue and Volume Forecast, by Technology

13.2.7. Market Revenue and Volume Forecast, by Application

13.2.8. Market Revenue and Volume Forecast, by End User

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Sample Type

13.2.9.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.2.9.3. Market Revenue and Volume Forecast, by Technology

13.2.10. Market Revenue and Volume Forecast, by Application

13.2.11. Market Revenue and Volume Forecast, by End User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Sample Type

13.2.12.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.2.12.3. Market Revenue and Volume Forecast, by Technology

13.2.12.4. Market Revenue and Volume Forecast, by Application

13.2.13. Market Revenue and Volume Forecast, by End User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Sample Type

13.2.14.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.2.14.3. Market Revenue and Volume Forecast, by Technology

13.2.14.4. Market Revenue and Volume Forecast, by Application

13.2.15. Market Revenue and Volume Forecast, by End User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Sample Type

13.3.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.3.3. Market Revenue and Volume Forecast, by Technology

13.3.4. Market Revenue and Volume Forecast, by Application

13.3.5. Market Revenue and Volume Forecast, by End User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Sample Type

13.3.6.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.3.6.3. Market Revenue and Volume Forecast, by Technology

13.3.6.4. Market Revenue and Volume Forecast, by Application

13.3.7. Market Revenue and Volume Forecast, by End User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Sample Type

13.3.8.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.3.8.3. Market Revenue and Volume Forecast, by Technology

13.3.8.4. Market Revenue and Volume Forecast, by Application

13.3.9. Market Revenue and Volume Forecast, by End User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Sample Type

13.3.10.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.3.10.3. Market Revenue and Volume Forecast, by Technology

13.3.10.4. Market Revenue and Volume Forecast, by Application

13.3.10.5. Market Revenue and Volume Forecast, by End User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Sample Type

13.3.11.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.3.11.3. Market Revenue and Volume Forecast, by Technology

13.3.11.4. Market Revenue and Volume Forecast, by Application

13.3.11.5. Market Revenue and Volume Forecast, by End User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Sample Type

13.4.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.4.3. Market Revenue and Volume Forecast, by Technology

13.4.4. Market Revenue and Volume Forecast, by Application

13.4.5. Market Revenue and Volume Forecast, by End User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Sample Type

13.4.6.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.4.6.3. Market Revenue and Volume Forecast, by Technology

13.4.6.4. Market Revenue and Volume Forecast, by Application

13.4.7. Market Revenue and Volume Forecast, by End User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Sample Type

13.4.8.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.4.8.3. Market Revenue and Volume Forecast, by Technology

13.4.8.4. Market Revenue and Volume Forecast, by Application

13.4.9. Market Revenue and Volume Forecast, by End User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Sample Type

13.4.10.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.4.10.3. Market Revenue and Volume Forecast, by Technology

13.4.10.4. Market Revenue and Volume Forecast, by Application

13.4.10.5. Market Revenue and Volume Forecast, by End User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Sample Type

13.4.11.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.4.11.3. Market Revenue and Volume Forecast, by Technology

13.4.11.4. Market Revenue and Volume Forecast, by Application

13.4.11.5. Market Revenue and Volume Forecast, by End User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Sample Type

13.5.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.5.3. Market Revenue and Volume Forecast, by Technology

13.5.4. Market Revenue and Volume Forecast, by Application

13.5.5. Market Revenue and Volume Forecast, by End User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Sample Type

13.5.6.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.5.6.3. Market Revenue and Volume Forecast, by Technology

13.5.6.4. Market Revenue and Volume Forecast, by Application

13.5.7. Market Revenue and Volume Forecast, by End User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Sample Type

13.5.8.2. Market Revenue and Volume Forecast, by Nucleic Acid Type (Downstream Application)

13.5.8.3. Market Revenue and Volume Forecast, by Technology

13.5.8.4. Market Revenue and Volume Forecast, by Application

13.5.8.5. Market Revenue and Volume Forecast, by End User

Chapter 14. Company Profiles

14.1. QIAGEN

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. BioChain Institute, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ProteoGenex, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Amsbio (AMS Biotechnology)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Asterand Bioscience (BioIVT brand)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Genomic Testing Cooperative

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Aperiomics

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Genentech Tissue Repository

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Novogene Co., Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Norgen Biotek Corp.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global FFPE tissue samples for genomics study and analysis market is expected to increase from USD 937.04 million in 2024 to USD 1,548.29 million by 2034.

The FFPE tissue samples for genomics study and analysis market is expected to grow at a compound annual growth rate (CAGR) of around 5.15% from 2025 to 2034.

The major players in the FFPE tissue samples for genomics study and analysis market include Thermo Fisher Scientific, Horizon Discovery (Revvity), QIAGEN, Abcam plc, BioChain Institute, Inc., OriGene Technologies, Inc., Indivumed GmbH, ProteoGenex, Inc., USBiological Life Sciences, Amsbio (AMS Biotechnology), BioIVT Tissue Solutions Ltd (a BioIVT company), Tristar Technology Group, Asterand Bioscience (BioIVT brand), Genomic Testing Cooperative, Aperiomics, Genentech Tissue Repository, iSpecimen Inc., Novogene Co., Ltd., and Norgen Biotek Corp.

The driving factors of the FFPE tissue samples for genomics study and analysis market are the increasing workload of histopathologists and the complexity of medical cases, with the necessity for faster and more efficient tissue analysis, drive the demand for advanced tissue processing techniques

North America region will lead the global FFPE tissue samples for genomics study and analysis market during the forecast period 2025 to 2034.